rs10871700 - LINC01899 - CBLN2
Magnitude 4.5 · 1 study on file
Reported associations
-
Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink - Unknown journal (n.d.) · Unknown authors · PubMed 31220337
ABSTRACT: Statins can be associated with myopathy. We have undertaken a genomewide association study (GWAS) to discover and validate genetic risk factors for statin‐induced myopathy in a "real‐world" setting. One hundred thirty‐five patients with statin myopathy recruited via the UK Clinical Practice Research Datalink were genotyped using the Illumina OmniExpress Exome version 1.0 Bead Chip and compared with the Wellcome Trust Case‐Control Consortium (n = 2,501). Nominally statistically significant single nucleotide polymorphism (SNP) signals in the GWAS (P < 5 × 10−5) were further evaluated in several independent cohorts (comprising 332 cases and 449 drug‐tolerant controls). Only one (rs4149056/c.521C>T in the SLCO1B1 gene) SNP was genomewide significant in the seve
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
atorvastatin risk with your prescriber Moderate
rs10871700 is associated with 3.3-fold increased risk of atorvastatin-induced myopathy in GWAS data
discuss statin choice with doctor; consider alternatives if atorvastatin is planned or current
Screening
-
muscle pain, weakness, or dark urine if taking statins Moderate
increased myopathy susceptibility requires vigilant surveillance for early warning signs
report muscle symptoms immediately; consider statin discontinuation if myopathy suspected